industry · Updated 2026-07-06
How Biotech Companies Can Optimize R&D Spend with the Right Corporate Card
Biotech firms require specialized card programs from Brex, Ramp, and Rho to manage high-cost lab equipment and NIH grant compliance requirements.
Quick answer
TL;DR
Biotech R&D spend optimization requires high-limit corporate cards that bypass personal guarantees while offering automated grant tracking for NIH/NSF compliance. Leading platforms like Brex and Ramp provide industry-specific 10-20x higher limits than traditional banks, catering to the capital-heavy nature of clinical trials and hardware procurement.
- •Brex for Life Sciences offers up to 20x higher credit limits by assessing venture backing rather than cash flow.
- •Ramp's AI automated accounting integrates with NetSuite to categorize R&D tax credit eligible expenses instantly.
- •Rho provides a 1.25% to 1.75% cashback model that sustains operational runways during pre-revenue research phases.
- •Airbase offers advanced Bill Pay features essential for managing high-ticket laboratory equipment global procurement.
- •Mercury provides specialized venture debt and treasury management to safeguard capital raised in Series A/B rounds.
Breaking the Personal Guarantee Barrier
Traditional business credit cards often require a personal guarantee from founders, which is suboptimal for high-burn biotech startups. Modern corporate card issuers like Brex and Ramp have pioneered the venture-backed underwriting model. This approach evaluates the company’s funding rounds, such as those led by ARCH Venture Partners or Flagship Pioneering, rather than the individual’s credit score. By securing limits based on 10% to 20% of the cash balance held in the business account, biotechs can procure high-cost reagents and lab consumables from vendors like Thermo Fisher Scientific without hitting ceiling limits prematurely.
Automating Grant Tracking and Compliance
For companies receiving NIH or SBIR grants, strict fund segregation and expense reporting are mandatory to avoid audit failures. The Rho and Ramp platforms allow for the creation of virtual cards designated for specific grant projects. This ensures that every dollar spent is tagged with the correct accounting code at the time of swipe. By integrating these cards with ERP systems like NetSuite or Sage Intacct, biotech finance teams can generate real-time reports that satisfy federal reporting requirements, reducing the administrative load on Principal Investigators during the 2026 fiscal year.
Managing Global Clinical Trial Logistics
As drug development moves into Phase II and III trials, spend often becomes international. Airbase and Brex provide robust multi-currency support and localized VAT tracking, which are essential when working with Contract Research Organizations (CROs) like IQVIA or LabCorp. Using virtual cards for global travel and site-specific petty cash allows for instantaneous visibility into trial spending. This transparency helps biotech CFOS maintain tighter control over the burn rate, ensuring that capital is preserved for the next critical milestone in the development pipeline.
Maximizing R&D Tax Credit Capture
Capturing every dollar of the Research and Development Tax Credit is vital for extending a biotech’s runway. Ramp and Mercury utilize AI-driven expense categorization to flag transactions that qualify for the tax credit under Section 174 of the Internal Revenue Code. By tagging equipment rentals, laboratory supplies, and software subscriptions like Benchling or BenchSci specifically as R&D qualifiers, firms ensure they are prepared for tax season. This automated documentation reduces the risk of missed credits, which can often represent 10% or more of annual spend for seed-stage life science companies.
Securing High-Value Lab Equipment
Procuring mass spectrometers, flow cytometers, and PCR machines involves high-ticket transactions that can exceed $100,000. Traditional $25,000 credit limits are insufficient for these needs. Corporate cards tailored for biotech allow for temporary limit increases or one-time virtual cards specifically for large-scale hardware acquisitions. Furthermore, some issuers offer physical security features and enhanced fraud protection for these large transactions, ensuring that the supply chain for sensitive laboratory instrumentation remains uninterrupted during critical research windows.
Pros
- +Venture-backed underwriting eliminates the need for personal assets as collateral for cards.
- +Virtual cards enable instant budget controls for laboratory managers and lab techs.
- +Integrated Bill Pay streamlines payments to CROs and specialized research vendors.
- +High-yield treasury accounts often accompany cards to maximize interest on unspent funding.
Cons
- −May require a minimum cash balance of $50,000 to $250,000 to maintain account status.
- −Heavy reliance on venture funding for limit calculations can lead to sudden limit drops.
- −Reward structures might be less favorable compared to high-fee consumer luxury cards.
Frequently asked
Which corporate card is best for NIH grant tracking?
Ramp is widely considered the best for NIH grant tracking due to its ability to create project-specific virtual cards with mandatory memo fields and automated GL coding.
Do biotech corporate cards require a personal guarantee?
No, specialized providers like Brex, Rho, and Ramp use business-only underwriting based on cash balances and funding history.
How high can I set the credit limit for lab equipment?
Providers like Brex offer limits up to 20% of your total cash balance, which can frequently reach several million dollars for Series A firms.
Can these cards integrate with Benchling software?
While most cards do not integrate directly into ELNs, they sync with NetSuite which acts as the bridge for laboratory financial management.
Are there specific rewards for biotech spending?
Brex for Life Sciences specifically offers multipliers on lab supplies and conference travel, providing higher ROI on common biotech expenses.
What happens to the credit limit if funding runs low?
Because limits are dynamic, they may decrease as cash is burned; however, Rho offers more stable limits for companies with recurring revenue or predictable burn.
